학술논문
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
Document Type
article
Author
Hirokazu Takahashi; Takaomi Kessoku; Miwa Kawanaka; Michihiro Nonaka; Hideyuki Hyogo; Hideki Fujii; Tomoaki Nakajima; Kento Imajo; Kenichi Tanaka; Yoshihito Kubotsu; Hiroshi Isoda; Satoshi Oeda; Osamu Kurai; Masato Yoneda; Masafumi Ono; Yoichiro Kitajima; Ryo Tajiri; Ayako Takamori; Atsushi Kawaguchi; Shinichi Aishima; Masayoshi Kage; Atsushi Nakajima; Yuichiro Eguchi; Keizo Anzai
Source
Hepatology Communications, Vol 6, Iss 1, Pp 120-132 (2022)
Subject
Language
English
ISSN
2471-254X
Abstract
Sodium glucose cotransporter‐2 inhibitors (SGLT2is) are now widely used to treat diabetes, but their effects on nonalcoholic fatty liver disease (NAFLD) remain to be determined. We aimed to evaluate the effects of SGLT2is on the pathogenesis of NAFLD. A multicenter, randomized, controlled trial was conducted in patients with type 2 diabetes with NAFLD. The changes in glycemic control, obesity, and liver pathology were compared between participants taking ipragliflozin (50 mg/day for 72 weeks; IPR group) and participants being managed without SGLT2is, pioglitazone, glucagon‐like peptide‐1 analogs, or insulin (CTR group). In the IPR group (n = 25), there were significant decreases in hemoglobin A1c (HbA1c) and body mass index (BMI) during the study (HbA1c, −0.41%, P